Understanding the Role of Airway Mucus Occlusions in Canadians With Asthma, COPD, and Chronic Cough
Networks
-
Datasets
-
Variables
-
The primary objective of this study is to evaluate the relationship of mucus plugging, quantified by CT mucus score and/or total number of mucus plugs, with sputum rheology and airway inflammatory phenotypes in a Canadian population diagnosed with asthma, COPD and Chronic Cough compared with healthy participants between baseline and 2-year follow-up.
The secondary objective is to investigate the impact of mucus plug burden on both objective and subjective clinical outcomes, as well as to identify clinical, physiological, inflammatory, and molecular predictors of persistent, incidental, and resolved mucus plugging.
- Start Year
- 2025
- Supplementary Information
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Cohort
- Follow Up
- After the first visit, participants with lung diseases are followed every 4 months and at 2 years.
Recruitment
- Recruitment Target
-
- Individuals
Number of Participants
- Number of Participants
- 340
- Number of Participants with Biological Samples
- 340
- Supplementary Information
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
Availability of access information
By contacting the study representative
Sector of research
| Possible Access to Data | Possible Access to Biosamples | |
|---|---|---|
| Investigators from the public sector | ||
| Investigators from the private sector | ||
| Investigators from not-for-profit organization |
Transfer
| Possible Access to Data | Possible Access to Biosamples | |
|---|---|---|
| Can leave the study facility | ||
| Can leave the country |
Cost
| Possible Access to Data | Not yet defined |
| Possible Access to Biosamples | Not yet defined |
Cost reduction for co-analyses
| Possible Access to Data | |
| Possible Access to Biosamples |
Timeline
Populations
The population is composed of individuals with a diagnosis of moderate-to-severe asthma confirmed by a respiratory physician, and/or a history of objective test evidence or a specialist’s past confirmation.
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Quebec city, Montreal, Ottawa, London, Sherbrooke, Hamilton, Vancouver
- Ethnic Origin
-
- Health Status
-
- Inclusion criteria:
* Respiratory physician–confirmed diagnosis of moderate-to-severe asthma (GINA Step 4 & Step 5).
* Individuals with historical objective evidence of asthma and/or specialist/respirologist confirmation (post-bronchodilator reversibility and/or methacholine bronchoprovocation test PC20 < 8 mg/mL).
Exclusion criteria: * Individuals who have a history of heart attack or hospitalization for other heart problems, stroke, aortic or cerebral aneurysm, detached retina, or eye surgery within the previous 6 months of recruitment. * Individuals with memory, cognitive, or psychiatric limitations that may prevent optimal participation. * Individuals with an active or current history of other pulmonary disorders (e.g., pulmonary embolism, pulmonary hypertension, lung cancer) or who are suspected to have ciliary dyskinesia.
- Inclusion criteria:
* Respiratory physician–confirmed diagnosis of moderate-to-severe asthma (GINA Step 4 & Step 5).
* Individuals with historical objective evidence of asthma and/or specialist/respirologist confirmation (post-bronchodilator reversibility and/or methacholine bronchoprovocation test PC20 < 8 mg/mL).
- Other Criteria
- Exclusion criteria: * Individuals who cannot perform spirometry. * Individuals who cannot be involved in another interventional clinical trial. * Pregnant or breastfeeding women. * Individuals who are current smokers (including marijuana or vaping), have a smoking history of more than 10 pack-years (one pack per day for over 10 years), or have smoked within the last 6 months. * Exacerbation within 4 weeks of recruitment. * Preterm birth (less than 36 weeks gestation) or perinatal complications. * Individuals who are currently using mucolytic medications (e.g., inhaled hypertonic saline, inhaled DNase, or inhaled N-acetyl-cysteine). * Individuals who are treated with current biologic therapy: anti-IgE mAb within 130 days, anti-IL-4/4R, IL-5/5R, IL-13, or TSLP within 2 months or 5 half-lives whichever is longer prior to visit 1.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are recruited through the CANMuc recruiting sites located across six Canadian academic health centres: * McMaster University / St. Joe’s Healthcare Hamilton (Hamilton, ON) * Western University / St. Joseph’s Healthcare London (London, ON) * University of British Columbia / St. Paul’s Hospital (Vancouver, BC) * Université de Sherbrooke / Centre hospitalier universitaire de Sherbrooke (CHUS) (Sherbrooke, QC) * Université Laval / Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) (Québec City, QC) * McGill University / McGill University Health Centre (MUHC) (Montréal, QC)
Number of Participants
- Number of Participants
- 100
- Number of Participants with Biological Samples
- 100
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
CANMuc - Asthma Group - Visit 1
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and ... | 2025-01 | |
| 1 |
CANMuc - Asthma Group - First telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2025-05 | |
| 2 |
CANMuc - Asthma Group - Second telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2025-09 | |
| 3 |
CANMuc - Asthma Group - Third telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-01 | |
| 4 |
CANMuc - Asthma Group - Fourth telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-05 | |
| 5 |
CANMuc - Asthma Group - Fifth telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-09 | |
| 7 |
CANMuc - Asthma Group - Visit 2
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and ... | 2027-01 |
The population is composed of individuals diagnosed by COPD (Chronic Obstructive Pulmonary Disease) that is moderate-to-severe according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria as confirmed by a respiratory physician, and/or a CAT (COPD Assessment Test) score ≥10 or mMRC (Modified Medical Research Council Dyspnea Scale) score ≥ 2.
Selection Criteria
- Minimum age
-
40
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Quebec city, Montreal, Ottawa, London, Sherbrooke, Hamilton, Vancouver
- Ethnic Origin
-
- Health Status
-
- Inclusion criteria:
* Respiratory physician–confirmed diagnosis of COPD that is moderate-to-severe according to GOLD criteria (post-bronchodilator FEV1/FVC < LLN and FEV1 < 80% predicted).
* CAT score ≥ 10 or mMRC score ≥ 2.
Exclusion criteria: * Individuals who have had a heart attack or hospitalization for other heart problems, stroke, aortic or cerebral aneurysm, detached retina, or eye surgery within the previous 6 months of recruitment. * Individuals with an active or current history of other pulmonary disorders (e.g., pulmonary embolism, pulmonary hypertension, lung cancer) or who are suspected to have ciliary dyskinesia. * Individuals with memory, cognitive, or psychiatric limitations that may prevent optimal participation.
- Inclusion criteria:
* Respiratory physician–confirmed diagnosis of COPD that is moderate-to-severe according to GOLD criteria (post-bronchodilator FEV1/FVC < LLN and FEV1 < 80% predicted).
* CAT score ≥ 10 or mMRC score ≥ 2.
- Other Criteria
- Exclusion criteria: * Individuals who cannot perform spirometry. * Individuals who cannot be involved in another interventional clinical trial. * Pregnant or breastfeeding women. * Individuals who are current smokers (including marijuana or vaping), have a smoking history of more than 10 pack-years (one pack per day for over 10 years), or have smoked within the last 6 months. * Exacerbation within 4 weeks of recruitment. * Preterm birth (less than 36 weeks gestation) or perinatal complications. * Individuals who are currently using mucolytic medications (e.g., inhaled hypertonic saline, inhaled DNase, or inhaled N-acetyl-cysteine). * Treatment with current biologic therapy: anti-IgE mAb within 130 days, anti-IL-4/4R, IL-5/5R, IL-13, or TSLP within 2 months or 5 half-lives whichever is longer prior to Visit 1.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are recruited through the CANMuc recruiting sites located across six Canadian academic health centres: * McMaster University / St. Joe’s Healthcare Hamilton (Hamilton, ON) * Western University / St. Joseph’s Healthcare London (London, ON) * University of British Columbia / St. Paul’s Hospital (Vancouver, BC) * Université de Sherbrooke / Centre hospitalier universitaire de Sherbrooke (CHUS) (Sherbrooke, QC) * Université Laval / Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) (Québec City, QC) * McGill University / McGill University Health Centre (MUHC) (Montréal, QC)
Number of Participants
- Number of Participants
- 80
- Number of Participants with Biological Samples
- 80
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
CANMuc - COPD Group - Visit 1
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and ... | 2025-01 | |
| 1 |
CANMuc - COPD Group - First telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2025-05 | |
| 2 |
CANMuc - COPD Group - Second telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2025-09 | |
| 3 |
CANMuc - COPD Group - Third telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-01 | |
| 4 |
CANMuc - COPD Group - Fourth telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-05 | |
| 5 |
CANMuc - COPD Group - Fifth telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-09 | |
| 6 |
CANMuc - COPD Group - Visit 2
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and ... | 2027-01 |
The population is composed of individuals diagnosed with refractory Chronic Cough (RCC) and Unexplained Chronic Cough (UCC) lasting more than a year.
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Quebec City, Montreal, Ottawa, London, Sherbrooke, Hamilton, Vancouver
- Ethnic Origin
-
- Health Status
-
- Inclusion criteria:
* Individuals with a physician-confirmed diagnosis of Refractory Chronic Cough (RCC) or Unexplained Chronic Cough (UCC) lasting more than 1 year.
Exclusion criteria: * Individuals who have had a heart attack or hospitalization for other heart problems, stroke, aortic or cerebral aneurysm, detached retina, or eye surgery within the previous 6 months of recruitment. * Individuals with an active or current history of other pulmonary disorders (e.g., pulmonary embolism, pulmonary hypertension, lung cancer) or who are suspected to have ciliary dyskinesia. * Individuals with memory, cognitive, or psychiatric limitations that may prevent optimal participation.
- Inclusion criteria:
* Individuals with a physician-confirmed diagnosis of Refractory Chronic Cough (RCC) or Unexplained Chronic Cough (UCC) lasting more than 1 year.
- Other Criteria
- Inclusion criteria: * Individuals with a normal chest radiograph. * Individuals with no airflow obstruction (FEV1/FVC > LLN). Exclusion criteria: * Individuals who cannot perform spirometry. * Individuals who cannot be involved in another interventional clinical trial. * Pregnant or breastfeeding women. * Individuals who are current smokers (including marijuana or vaping), have a smoking history of more than 10 pack-years (one pack per day for over 10 years), or have smoked within the last 6 months. * Exacerbation within 4 weeks of recruitment. * Preterm birth (less than 36 weeks gestation) or perinatal complications. * Individuals who are currently using mucolytic medications (e.g., inhaled hypertonic saline, inhaled DNase, or inhaled N-acetyl-cysteine) or ACE-inhibitors. * Individuals who are currently treated with biologic therapy: anti-IgE mAb within 130 days, anti-IL-4/4R, IL-5/5R, IL-13, or TSLP within 2 months or 5 half-lives whichever is longer prior to Visit 1.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are recruited through the CANMuc recruiting sites located across six Canadian academic health centres: * McMaster University / St. Joe’s Healthcare Hamilton (Hamilton, ON) * Western University / St. Joseph’s Healthcare London (London, ON) * University of British Columbia / St. Paul’s Hospital (Vancouver, BC) * Université de Sherbrooke / Centre hospitalier universitaire de Sherbrooke (CHUS) (Sherbrooke, QC) * Université Laval / Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) (Québec City, QC) * McGill University / McGill University Health Centre (MUHC) (Montréal, QC)
Number of Participants
- Number of Participants
- 60
- Number of Participants with Biological Samples
- 60
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
CANMuc - Chronic Cough Group - Visit 1
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and ... | 2025-01 | |
| 1 |
CANMuc - Chronic Cough Group - First telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2025-05 | |
| 2 |
CANMuc - Chronic Cough Group - Second telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2025-09 | |
| 3 |
CANMuc - Chronic Cough Group - Third telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-01 | |
| 4 |
CANMuc - Chronic Cough Group - Fourth telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-05 | |
| 5 |
CANMuc - Chronic Cough Group - Fifth telemonitoring visit
|
Information on medications use, patient-initiated healthcare utilization events for respiratory illness, emergency visits, hospitalizations, and physician visits for respiratory illness is ... | 2026-09 | |
| 6 |
CANMuc - Chronic Cough Group - Visit 2
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and ... | 2027-01 |
The population is composed of individuals who have no history of respiratory disease or other pulmonary disorders and no use of inhaled medications or corticosteroids.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
79
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Quebec city, Montreal, Ottawa, London, Sherbrooke, Hamilton, Vancouver
- Ethnic Origin
-
- Health Status
-
- Inclusion criteria:
* Individuals with no history of respiratory disease or other pulmonary disorders, and no use of inhaled medications or corticosteroids.
* Individuals must have normal spirometry and an mMRC ≤ 1 (Modified Medical Research Council Dyspnea Scale).
Exclusion criteria: * Individuals who have had a heart attack or hospitalization for other heart problems, stroke, aortic or cerebral aneurysm, detached retina, or eye surgery within the previous 6 months of recruitment. * Individuals with memory, cognitive, or psychiatric limitations that may prevent optimal participation. * Individuals with an active or current history of lung cancer or any other malignancy within the past 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, nonmetastatic prostate cancer, or Stage I uterine cancer. * Individuals with an active or current history of other pulmonary disorders (e.g., pulmonary embolism, pulmonary hypertension, lung cancer) or who are suspected to have ciliary dyskinesia.
- Inclusion criteria:
* Individuals with no history of respiratory disease or other pulmonary disorders, and no use of inhaled medications or corticosteroids.
* Individuals must have normal spirometry and an mMRC ≤ 1 (Modified Medical Research Council Dyspnea Scale).
- Other Criteria
- Exclusion criteria: * Individuals who have had a heart attack or hospitalization for other heart problems, stroke, aortic or cerebral aneurysm, detached retina, or eye surgery within the previous 6 months. * Individuals who cannot perform spirometry. * Individuals who cannot be involved in another interventional clinical trial. * Individuals who are current smokers (including marijuana or vaping), have a smoking history of more than 10 pack-years (one pack per day for over 10 years), or have smoked within the last 6 months. * Pregnant or breastfeeding women. * Acute infection within the previous 4 weeks. * Preterm birth (≤ 36 weeks gestation) or perinatal complications. * Individuals who are currently on treatment with any biologic or immunosuppressive therapy.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are recruited through the CANMuc recruiting sites located across six Canadian academic health centres: * McMaster University / St. Joe’s Healthcare Hamilton (Hamilton, ON) * Western University / St. Joseph’s Healthcare London (London, ON) * University of British Columbia / St. Paul’s Hospital (Vancouver, BC) * Université de Sherbrooke / Centre hospitalier universitaire de Sherbrooke (CHUS) (Sherbrooke, QC) * Université Laval / Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) (Québec City, QC) * McGill University / McGill University Health Centre (MUHC) (Montréal, QC)
Number of Participants
- Number of Participants
- 100
- Number of Participants with Biological Samples
Data Collection Event
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and concomitant medications.
Information is collected on asthma control, respiratory health status, COPD symptoms, cough-related quality of life, breathlessness, autoimmune conditions, and cough severity through the Asthma Control Questionnaire (ACQ-5), St. George’s Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), Cough and Sputum Assessment Questionnaire (CASA-Q), modified Medical Research Council Dyspnea Scale (mMRC), Autoimmune Questionnaire, McMaster Cough Severity Questionnaire (MCSQ), Leicester Cough Questionnaire (LCQ), and the Cough Severity Visual Analog Scale (VAS).
Pre- and post-bronchodilator spirometry, pre- and post-bronchodilator oscillometry (at specified sites), and a 6-minute walk test are performed.
Urine is collected for females of child-bearing potential (less than 50 years) and who are postmenopausal for less than one year.
Induced sputum and blood are collected.
Post-bronchodilator high-resolution computed tomography (HRCT) of the chest for residual volume (RV) and total lung capacity (TLC), as well as post-bronchodilator ^129Xe ventilation and ^1H MRI (only at specified sites and only in participants without contraindications) are performed. Fractional exhaled nitric oxide (FeNO) is also measured as part of the lung function assessment.
24-hour cough is monitored through the VitaloJAK portable cough monitoring device.
- Start Date
-
2024-01
- Data sources
-
- Questionnaires
- Physical measures
- Biosamples
- Other : VitaloJAK
- Data sources - Biosamples
-
- Blood
- Urine
- Other : Induced sputum
Classifications
- Socio-demographic and economic characteristics
- Lifestyle and behaviours
- Birth, pregnancy and reproductive health history
- Perception of health, quality of life, development and functional limitations
- Diseases
- Symptoms and signs
- Medication and supplements
- Non-pharmacological interventions
- Health and community care services utilization
- Death
- Physical measures and assessments
- Laboratory measures
- Cognition, personality and psychological measures and assessments
- Life events, life plans, beliefs and values
- Preschool, school and work life
- Social environment and relationships
- Physical environment
- Administrative information
Socio-demographic and economic characteristics
Lifestyle and behaviours
Diseases
Symptoms and signs
Medication and supplements
Health and community care services utilization
Physical measures and assessments
Laboratory measures
Administrative information